The NFL will spend up to $1 million funding up to five studies that will examine how to better help players ease their pain and find alternatives to opioids.
Among those potential alternatives: marijuana and other cannabis-derived products.
The league announced its call for research proposals Tuesday. The league and the NFL Players Association formed a joint pain management committee in 2019 to help find alternatives to opioids and give players and league medical staffs information on pain management.
Dr. Allen Sills, the NFL's chief medical officer, said there are a lot of great ideas and important research that need to be funded.
“This is really not an NFL issue or a sports issue,” Sills said. "This is a societal issue, which is how can we better understand and treat pain and what are the alternatives that may be out there for treatment in addition to opioids which have long been used.”
Some retired NFL players, including Nate Jackson and Kyle Turley, have spoken out about their use of marijuana during their time in the league and said it's a better way of managing pain than the drugs prescribed by team doctors. The league prohibits marijuana use by players.
Jeff Miller, the NFL’s executive vice president overseeing player health and safety, said the league’s policy on substance abuse is not changing, with Tuesday’s announcement focused only on proposals and research.
The pain management committee held two forums in 2020 to learn more about cannabidiol science and manufacturing and now wants more information on how cannabinoids not only affect pain but the performance of NFL players.
Dr. Kevin Hill is co-chairman of the joint pain management committee and wrote a book titled “Marijuana: The Unbiased Truth about the World's Most Popular Weed." He said players have been asking about cannabis and cannabidiol CBD. Hill said they've tried to provide the best information on a controversial topic.
“Unfortunately, the level of interest right now far exceeds the level of evidence supporting the use of medical cannabis for pain,” Hill said.
Hill, also director of addiction psychiatry at Beth Israel Deaconess Medical Center and associate professor of psychiatry at Harvard Medical School, said there are flaws in each of the controlled trials despite some evidence supporting the use of medical cannabis for pain.
“That’s why we put out this request for proposals so that we can collectively with the PA, the players association, move towards finding better treatments for pain. Those treatments may include cannabis, and they may include CBD,” Hill said.
The NFL opened the application process Tuesday. The league wants initial proposals studying how cannabinoids can help players manage pain daily and after surgery, how cannabis or cannabinoids affect players' athletic performance, and how other non-pharmaceutical treatments can benefit players.
Proposals must be submitted by July 31 with the pain management committee paring down submissions for formal presentations. Those will presented in November with a final decision the week of Dec. 6.
The FDA has granted emergency use authorization to Pfizer's pill to treat covid-19. The treatment, called Paxlovid, is the first antiviral covid-19 pill that people can take at home.
Pfizer says the pill can reduce the risk of severe illness by 90 percent and is intended for people at high risk for severe disease, including those over 65, people with obesity, diabetes, or a weakened immune system. Professor Peter Pitts, Founder, Center for Medicine in the Public Interest & Former FDA Associate joined Wake Up with Cheddar to discuss.
Ahead of a four day week for the markets due to the upcoming Christmas holiday, investors hoping for a quiet end to the year, or even a Santa Claus rally, may not be in luck. Investors are still digesting the latest from the Fed regarding a quicker than expected taper, as well as ever increasing blow back as the Omicron variant spreads. Octavio Marenzi, CEO of Opimas LLC, explains why the markets have been so volatile ever since the emergence of the latest variant and what to expect going forward into 2022.
Carlo and Baker cover the heartening news on the Covid front ahead of the holiday, plus President Biden punting student loan repayments again, a new space telescope and Love, Hate, Ate: Christmas Eve Eve Edition!
Pfizer, one of the makers of a currently available COVID-19 vaccine, has taken another critical step forward in combatting the pandemic by getting regulatory approval for Paxlovid, a pill treatment rather than IV or injection as others have been. Dr. Purvi Parikh, an immunologist with the Allergy and Asthma Network, spoke to Cheddar about the ramifications of the authorization. "This is huge, especially because we know early treatment does keep people out of the hospital, especially with this antiviral," Parikh said. "The fact that people can start a regimen at home so they don't have to leave and further expose others is a big breakthrough." She also explained how the drug is a combination of two antiviral medications that are not without its risks but should be safe over the short term.
This year's worldwide semiconductor shortage limited the supply of everything from new cars to smartphones; and now, many in the chip industry expect the shortage to continue deep into 2022, and maybe even 2023. Semiconductor senior research analyst for Robert W. Baird & Co., Tristan Gerra, joins Cheddar News' Closing Bell to discuss.
Direct health care company Nomi Health recently raised $110 million in a Series A round. Nomi Health lets public and private organizations directly purchase healthcare at reduced costs, and pay providers in real-time. It also delivers healthcare directly to under-served communities via its fleet of mobile care units, which the company says is the largest in the country. Nomi Health says its mission is to improve the health care experience for all Americans. Nomi Health CEO Mark Newman joined Cheddar News' Closing Bell to discuss.
The airline industry says it is contending with staff shortages that threaten to hamper operations amid the COVID resurgence, andDelta Airlines CEO Ed Bastian called on the CDC to revise its guidance for vaccinated workers who test positive from a 10-day quarantine to just five. Chuck Liberman, chief investment officer and managing partner at Advisors Capital Management LLC, joined Cheddar to talk about the current guidance on isolation and why he believes the omicron variant calls for more relaxed guidance given its reportedly mild symptoms.
The boys discuss President Biden's plans to send out free rapid tests as the testing supply chain starts to buckle ahead of the holidays. Also, why aren't Americans having more babies, and The Matrix returns.
NASA is launching its new generation of space telescopes just before Christmas. The James Webb Space Telescope, set to launch on December 24th, will succeed the Hubble space telescope as the world's most powerful complex space observatory. The project has been 30 years in the making and is one of the most highly anticipated space science missions of the 21st century. Klaus Pontoppidan, astronomer and JWST Project Scientist at the Space Telescope Science Institute joined Cheddar's Opening Bell to discuss.
With Omicron becoming the dominant COVID-19 variant in the U.S., President Joe Biden announced that he will make 500 million rapid tests available to Americans in January 2022. Cheddar News speaks with Dr. Shereef Elnahal, President and CEO of University Hospital why testing is key to combatting the spread of the virus.
